Biomedical Engineering Reference
In-Depth Information
32. Franz-Montan, M.,
et al.
, Liposomal-benzocaine gel formulation: correla-
tion between in vitro assays and in vivo topical anesthesia in volunteers.
J
Liposome Res
, 2013. 23(1): p. 54-60.
33. Singh, H.P.,
et al.
, Elastic liposomal formulation for sustained delivery of col-
chicine: in vitro characterization and in vivo evaluation of anti-gout activity.
AAPS J
, 2009. 11(1): p. 54-64.
34. Hajos, F.,
et al.
, Inhalable liposomal formulation for vasoactive intestinal
peptide.
Int J Pharm
, 2008. 357(1-2): p. 286-94.
35. Yang, W.,
et al.
, Survivin downregulation by siRNA/cationic liposome com-
plex radiosensitises human hepatoma cells in vitro and in vivo.
Int J Radiat
Biol
, 2010. 86(6): p. 445-57.
36. Li, C.,
et al.
, RNA interference targeting human FAK and EGFR suppresses
human non-small-cell lung cancer xenograt growth in nude mice.
Cancer
Gene h er
, 2013. 20(2): p. 101-8.
37. Commander, N.J.,
et al.
, Liposomal delivery of p-ialB and p-omp25 DNA
vaccines improves immunogenicity but fails to provide full protection
against B. melitensis challenge.
Genet Vaccines h er
, 2010. 8: p. 5.
38. Ito, Y.,
et al.
, Evaluation of proinl ammatory cytokine production and liver
injury induced by plasmid DNA/cationic liposome complexes with various
mixing ratios in mice.
Eur J Pharm Biopharm
, 2009. 71(2): p. 303-9.
39. Park, J.,
et al.
, h e ef ect on bone regeneration of a liposomal vector to deliver
BMP-2 gene to bone grat s in peri-implant bone defects.
Biomaterials
, 2007.
28(17): p. 2772-82.
40. Qiao, W. and M. Zhou, Hydroxyl-modii ed cationic lipids with a carbamate
linkage as gene delivery vehicles.
European Journal of Lipid Science and
Te c h n o l o g y
, 2013. 115(5): p. 483-489.
41. Beisner, J.,
et al.
, Ei cient telomerase inhibition in human non-small cell
lung cancer cells by liposomal delivery of 2'-O-methyl-RNA.
J Pharm Sci
,
2009. 98(5): p. 1765-74.
42. De Rosa, G.,
et al.
, Novel cationic liposome formulation for the delivery of
an oligonucleotide decoy to NF-kappaB into activated macrophages.
Eur J
Pharm Biopharm
, 2008. 70(1): p. 7-18.
43. Kashyap, M.,
et al.
, Down-Regulation of Nerve Growth Factor Expression in
the Bladder by Antisense Oligonucleotides as New Treatment for Overactive
Bladder.
J Urol
, 2013.
44. Aleku, M.,
et al.
, Atu027, a liposomal small interfering RNA formulation
targeting protein kinase N3, inhibits cancer progression.
Cancer Res
, 2008.
68(23): p. 9788-98.
45. Dass, C.R.,
et al.
, Downregulation of c-jun results in apoptosis-mediated
anti-osteosarcoma activity in an orthotopic model.
Cancer Biol h er
, 2008.
7(7): p. 1033-6.
46. Ye, L.,
et al.
, Angiomyogenesis using liposome based vascular endothelial
growth factor-165 transfection with skeletal myoblast for cardiac repair.
Biomaterials
, 2008. 29(13): p. 2125-37.
